CA2072123C - Inhibiteurs de la phosphorylase du nucleoside de la purine - Google Patents

Inhibiteurs de la phosphorylase du nucleoside de la purine

Info

Publication number
CA2072123C
CA2072123C CA002072123A CA2072123A CA2072123C CA 2072123 C CA2072123 C CA 2072123C CA 002072123 A CA002072123 A CA 002072123A CA 2072123 A CA2072123 A CA 2072123A CA 2072123 C CA2072123 C CA 2072123C
Authority
CA
Canada
Prior art keywords
compound
cyclo
amino
pyrrolo
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002072123A
Other languages
English (en)
Other versions
CA2072123A1 (fr
Inventor
John A. Secrist, Iii
Mark D. Erion
John A. Montgomery
Steven E. Ealick
Wayne C. Guida
Shri Niwas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocryst Pharmaceuticals Inc
Original Assignee
Biocryst Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/429,100 external-priority patent/US4985433A/en
Priority claimed from US07/429,097 external-priority patent/US5008270A/en
Priority claimed from US07/429,099 external-priority patent/US5008265A/en
Priority claimed from US07/429,098 external-priority patent/US4985434A/en
Application filed by Biocryst Pharmaceuticals Inc filed Critical Biocryst Pharmaceuticals Inc
Publication of CA2072123A1 publication Critical patent/CA2072123A1/fr
Application granted granted Critical
Publication of CA2072123C publication Critical patent/CA2072123C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/31—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/35—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/40—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002072123A 1989-10-31 1990-10-12 Inhibiteurs de la phosphorylase du nucleoside de la purine Expired - Fee Related CA2072123C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US07/429,100 US4985433A (en) 1989-10-31 1989-10-31 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US07/429,097 US5008270A (en) 1989-10-31 1989-10-31 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US429,097 1989-10-31
US429,100 1989-10-31
US429,098 1989-10-31
US07/429,099 US5008265A (en) 1989-10-31 1989-10-31 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US07/429,098 US4985434A (en) 1989-10-31 1989-10-31 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same
US429,099 1989-10-31
US44279889A 1989-11-29 1989-11-29
US442,798 1989-11-29
PCT/US1990/005756 WO1991006548A1 (fr) 1989-10-31 1990-10-12 Inhibiteurs de phosphorylase de nucleoside de purine

Publications (2)

Publication Number Publication Date
CA2072123A1 CA2072123A1 (fr) 1991-05-01
CA2072123C true CA2072123C (fr) 2001-06-12

Family

ID=27541578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002072123A Expired - Fee Related CA2072123C (fr) 1989-10-31 1990-10-12 Inhibiteurs de la phosphorylase du nucleoside de la purine

Country Status (9)

Country Link
EP (1) EP0500653A4 (fr)
JP (1) JP2866478B2 (fr)
AU (1) AU654264B2 (fr)
CA (1) CA2072123C (fr)
FI (1) FI103972B1 (fr)
HU (1) HUT61765A (fr)
LV (1) LV10100B (fr)
NO (1) NO301423B1 (fr)
WO (1) WO1991006548A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726311A (en) * 1989-11-29 1998-03-10 Biocryst Pharmaceuticals, Inc. 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
US5236926A (en) * 1992-02-03 1993-08-17 Warner-Lambert Company 9-substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors or PNP for pharmaceutical compositions
HUT71559A (en) * 1992-04-21 1995-12-28 Biocryst Pharm Inc 4-oxo-3h,5h-pyrrolo[3,2-d]pyrimidine and pharmaceutical compositions containing them
MX9702488A (es) * 1994-10-05 1998-04-30 Darwin Discovery Ltd Compuestos de purina y guanina como inhibidores de pnp.
GB9520363D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compounds
GB9520364D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compouundds
JP2002500658A (ja) * 1997-05-29 2002-01-08 ノバルティス アクチエンゲゼルシャフト ２−アミノ−７−（１−置換−２−ヒドロキシエチル）−３，５−ジヒドロピロロ［３，２−ｄ］ピリミジン−４−オン
US6174888B1 (en) 1998-05-28 2001-01-16 Novartis Ag 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones
JP4496586B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルアクリロニトリルの製造法及びその中間体
DE60336734D1 (de) * 2002-08-21 2011-05-26 Ind Res Ltd Sidasen
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
WO2009079797A1 (fr) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Composés et procédé pour le traitement du cancer
CA2999435A1 (fr) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Composes et methodes pour le traitement du vih

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5988484A (ja) * 1982-11-09 1984-05-22 Takeda Chem Ind Ltd 新規７−デアザプリン誘導体
CA1293727C (fr) * 1986-08-26 1991-12-31 Catherine Rose Kostlan 9-deazaguanines
CA1294960C (fr) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines en tant qu'immunomodulateurs
US4921858A (en) * 1986-10-24 1990-05-01 Warner-Lambert Company 7-deazaguanines as immunomodulators
DE3726044A1 (de) * 1987-02-11 1988-08-25 Bayer Ag Akarizide mittel auf basis von azomethinderivaten und azomethine des 2,3-diaminomaleinsaeurenitrils
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
ATE157363T1 (de) * 1989-02-27 1997-09-15 Biocryst Pharm Inc 9-substituierte-8-unsubstituierte-9-deazaguanin
US4985434A (en) * 1989-10-31 1991-01-15 Biocryst, Inc. 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same
US4985433A (en) * 1989-10-31 1991-01-15 Biocryst, Inc. 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same

Also Published As

Publication number Publication date
HUT61765A (en) 1993-03-01
AU6712590A (en) 1991-05-31
NO921679L (no) 1992-06-17
NO301423B1 (no) 1997-10-27
EP0500653A1 (fr) 1992-09-02
WO1991006548A1 (fr) 1991-05-16
FI921900A (fi) 1992-04-28
LV10100B (en) 1995-08-20
AU654264B2 (en) 1994-11-03
JP2866478B2 (ja) 1999-03-08
JPH05504551A (ja) 1993-07-15
EP0500653A4 (en) 1995-08-23
CA2072123A1 (fr) 1991-05-01
FI103972B (fi) 1999-10-29
NO921679D0 (no) 1992-04-29
LV10100A (lv) 1994-05-10
FI921900A0 (fi) 1992-04-28
FI103972B1 (fi) 1999-10-29
HU9201450D0 (en) 1992-09-28

Similar Documents

Publication Publication Date Title
CA2072123C (fr) Inhibiteurs de la phosphorylase du nucleoside de la purine
KR101081446B1 (ko) 2-치환페닐-5,7-디알킬-3,7-디하이드로피롤[2,3-ｄ]피리미딘-4-온유도체, 그의 제법 및 약학적 용도
US6441018B2 (en) Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
LT3448B (en) Inhibitors of purine nucleoside phosphorylase and process for preparing thereof
HU193799B (en) Process for producing 3-acyl-amino-methyl-imidazo-square bracket opened-1,2-a-square bracket closed-pyridine derivatives and pharmaceutical compositions containing them
SK76699A3 (en) Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments
WO1992014707A1 (fr) Derives de poly-4-aminopyrrole-2-carboxyamides, leurs procedes de preparation et compositions pharmaceutiques les contenant
US5008265A (en) 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
US5189039A (en) 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo[3,2d]pyrimidine and pharmaceutical uses and compositions containing the same
US5565463A (en) 9-subtituted-8-unsubstituted-9-deazaguanines
EP0638080A1 (fr) PYRIMIDINE 7-BISUBSTITUEE-METHYL-4-OXO-3H -, 5H --PYRROLO 3,2-d -], UTILISATION PHARMACEUTIQUE ET COMPOSITIONS CONTENANT LADITE PYRIMIDINE
US4985433A (en) 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same
CS242894B2 (en) Method of compounds production with a diazotized heterocyclic core
US5726311A (en) 7-disubstituted-methyl-4-oxo-3H,5H-pyrrolo 3,2-d!pyrimidine and pharmaceutical uses and compositions containing the same
EP1400522A1 (fr) Nouveaux composes de traitement de l'impuissance
US6103900A (en) Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
Su et al. Pyrimidines. 21. Novel reactions of 5‐cyano‐1, 3‐dimethyluracil with carbon nucleophiles. A facile preparation of certain pyrido [2, 3‐d] pyrimidines
US4980472A (en) Method of making (3-amino-1H-pyrazol-4-yl) (aryl)methanones
EP0110575A1 (fr) Acides 1-aroyle-5-oxo-2-pyrrolidinepropanoique et leurs esters
Elnagdi et al. Pyrimidine Derivatives and Related Compounds, V Synthesis of Some Isoxazolo [2, 3-a] pyrimidines. A New Ring System
EP1173420A2 (fr) Composes heterocycliques ayant une activite antitumorale
US6946554B2 (en) Process for the preparation of 9-deazaguanine derivatives
EP0816359B1 (fr) 4-Amino-2-uréido-pyrimidine-5-carboxamides, procédés pour leur préparation, médicaments contenant ces composés, et leur application
CH634069A5 (en) Process for preparing novel 7-substituted 7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
JP2001521483A (ja) ９−デアザグアニン誘導体の製造方法

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed